Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy

Yavuz D., Topcu G., Ozener C., Akalin S., Sirikci Ö.

CLINICAL ENDOCRINOLOGY, vol.63, no.5, pp.520-524, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 5
  • Publication Date: 2005
  • Doi Number: 10.1111/j.1365-2265.2005.02375.x
  • Journal Name: CLINICAL ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.520-524
  • Marmara University Affiliated: Yes

Abstract

Objective Three molecular forms of PRL with molecular weights of 23, 50-60 and > 100 kDa have been defined. The high-molecular-weight forms are called macroprolactin. Different immunoassays produce varyingly elevated results with macroprolactin-containing sera. The kidneys are reported to clear 25% of PRL from the circulation. Hyperprolactinaemia is seen in 20-75% of patients with chronic renal failure (CRF). PRL clearance rate has been reported to be reduced in CRF and the resulting hyperprolactinaemia is due to reduced renal function.